Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares gapped down prior to trading on Tuesday . The stock had previously closed at $18.31, but opened at $17.60. Daiichi Sankyo shares last traded at $18.23, with a volume of 10,744 shares.

Wall Street Analysts Forecast Growth

Separately, Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Daiichi Sankyo Trading Up 0.0%

The firm has a market capitalization of $34.70 billion, a price-to-earnings ratio of 16.80, a P/E/G ratio of 1.08 and a beta of -0.36. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. The company has a 50 day moving average price of $19.89 and a two-hundred day moving average price of $22.43.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.25 by $0.05. The company had revenue of $3.65 billion during the quarter, compared to analyst estimates of $3.88 billion. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. On average, research analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.73 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.